Case Report

Concomitant renal and splenic infarctions in a COVID-19-patient with a catastrophic thrombotic syndrome

Falmata Laouan Brem, MDa,∗, Taha Abu Al Tayef, MDb, Hammam Rasras, MDA, Omar El Mahi, PhDc, Noha El Ouafi, PhDc, Bazid Zakaria, PhDa

a Department of Cardiology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, Oujda, Morocco
b Department of Vascular surgery, Mohamed VI University Hospital Center, Mohamed I University, Oujda, Morocco
c Epidemiological Laboratory of Clinical Research and Public Health, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, Oujda, Morocco

ABSTRACT

Since the outbreak of the COVID-19 pandemic, thrombotic events have been accurately described in patients infected by the SARS-CoV-2, especially venous thromboembolism. However, the mystery of arterial thrombosis is still unclear. Here, we report the case of a 59-year-old man with diabetes mellitus, admitted for COVID-19-pneumonia complicated by pulmonary embolism, a thrombus in the aortic isthmus, the descending thoracic aorta associated with splenic and left renal infarctions, and an acute right limb ischemia. The etiological assessment of this catastrophic thrombotic syndrome showed no evidence for preexisting inherited or acquired thrombophilia. Our case emphasizes the hypercoagulability state in COVID-19-patient leading to both arterial and venous thromboembolisms and the need to establish adequate strategies for the diagnosis and management of thrombo-embolisms to prevent these potentially fatal complications.

© 2022 Published by Elsevier Inc. on behalf of University of Washington.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Since the outbreak of the novel coronavirus disease 2019 (COVID-19), there is increasing evidence of thrombotic events, especially in critical ill patients [1]. Moreover, this hypercoagulable state seems to induce both venous and arterial thrombosis [2]. Nonetheless, little is known about arterial thrombosis related to COVID-19 disease. In fact, some authors reported widespread vascular thrombosis with microangiopathy in the lungs from patients with Covid-19 during autopsy [3,4]. To date just a few cases of thrombotic arterial complications related to the COVID-19 infection have been reported. Herein, we report the case of a 59-year-old man who presented with a COVID-19...
infection, complicated by a catastrophic thrombotic syndrome including pulmonary embolism, aortic thrombosis and acute limb ischemia, associated with splenic and left renal infarctions.

Case presentation

A 59-year-old man with a past medical history of diabetes mellitus was admitted to the emergency department for sudden dyspnea after two weeks of cough, subjective fever, and asthenia. He was febrile at 39°C and hemodynamically stable on physical examination, but saturating 75% on room air. Biological findings revealed elevated white blood cells (WBC) at 15,000 elements/mm³ (normal range (NR): [4000-10,000]), with lymphopenia at 450 elements/mm³ (NR: 1500-4000), decreased level of platelets counts at 120,000 elements/mm³ (NR: 150,000-450,000); a high D-Dimer level at 33,620 ng/mL (NR: 0-500); a high level of fibrinogen at 4.5 g/L (NR: [1.5-3], elevated CRP at 189.88 mg/L (NR: 0-6); a high level of ferritin at 4150 ng/mL (NR: 30-300), and LDH at 1221 unit/L (NR: 140-245). The SARS-Cov-2 reverse transcriptase-polymerase chain reaction test (RT-PCR) was positive. The patient received Azithromycin, Ceftriaxone, hydroxychloroquine and prophylactic anticoagulation therapy with low-molecular-weight-heparin (LMWH).

The day after, the patient reported pain in the right lower limb. The physical examination revealed coolness, numbness and no peripheral pulse of the right popliteal, anterior tibial, posterior tibial, and dorsalis pedis artery were palpable. We emergently performed a venous and arterial doppler ultrasound that showed no vascular flow at the right popliteal artery level. An urgent blood test showed an elevated creatinine kinase (CK) level at 20,500 U/L (NR: 0-195 UI/l), and renal function was normal with creatinine level at 9.59 mg/L (NR: 6-12 mg/L).

An urgent chest, abdominal, and pelvic computed tomography angiography (CTA) revealed a filling defect in the left segmental pulmonary artery and typical patterns related to COVID-19 infection at the lung parenchyma, including peripheral distribution of ground-glass opacities associated with crazy paving as well as consolidation (Fig. 1, A, B, C), a thrombus in the aorta isthmus and the descending thoracic aorta (Fig. 2, A, B, C) associated with renal and splenic infarctions (Fig. 3). The lower limbs CTA showed an abrupt arrest in the right femoral artery. The patient underwent an emergent femoropopliteal Fogarty embolectomy by the vascular surgery department with a good final blood flow.

After embolectomy, the patient underwent anticoagulation treatment with low molecular weight heparin (LMWH) 60 mg twice a day. Two days after the embolectomy, the patient presented a poor clinical response. We discussed his case in a
multidisciplinary session then the patient underwent infracondylar amputation of the right lower limb. His condition improved and discharged 15 days later with anticoagulation treatment.

The etiological assessment of this catastrophic thrombotic syndrome showed no evidence for pre-existing inherited or acquired thrombophilia. (Protein S, protein C, and antithrombin III were normal, mutation for factor II and V Leiden and antiphospholipid antibodies were absent.

**Discussion**

Catastrophic thrombotic syndromes are distinguished by the rapid onset of multiple thromboembolic occlusions in various vascular beds [5]. Thromboembolic complications are commonly described in patients with COVID-19 disease [1]. However, the blood clots’ pathogenesis related to COVID-19 is still unclear. The pathophysiological mechanism proposed includes the three elements of Virchow’s triad. Endothelial cell dysfunction, blood flow stasis due to immobilization, and coagulation abnormalities such as elevated fibrinogen, factor VIII have been reported in patients with COVID-19 [3,6,7]. This state of hypercoagulability, seems to induce both venous and arterial thrombosis [2]. Nevertheless, little is known about the incidence of arterial thrombosis. A recent study has reported an incidence of 1.8% in 2021 confirmed-COVID-19-patients [8].

Berre et al. [9] have reported the first case of acute arterial thrombosis related to COVID-19 and was an association between aortic thrombosis and pulmonary embolism. Woehl B et al. have reported the first series of 4 cases of aortic thrombosis in COVID-19 patients. As 50% of these patients died, they suggested that the outcomes in patients infected by the SARS-cov2 affected by arterial thrombosis seem to be severe [10]. Then, a few reports of acute arterial thrombosis were described in the literature, which occurred in the mesenteric, limb and cerebral arteries [11]. Indeed, COVID-19-patients are at high risk for developing acute arterial thromboembolic complications, especially in large vessel distributions [12]. Kashi et al. [13] have reported a case series of seven severe arterial thrombotic events COVID19-patients despite the use of antiplatelet or anticoagulant therapy. Moreover, there has been a single report of arterial thrombosis in an ambulatory patient in recovery [14] and patients with a mild COVID-19 [15].

Our patient, who presented a catastrophic thrombotic syndrome (thrombotic storm) as reported in a previous single report, [16] required amputation after Fogarty embolectomy. Madani et al. reported a case of a 40-year-old with COVID-19 who required amputation of the right lower extremity due to acute limb ischemia [17]. The mortality reported in patients with arterial thrombosis is higher in COVID-19-patient than those without COVID-19, as well as the rate of amputation [18].

Regarding previous reports, including a concomitant renal and splenic infarction in a patient with COVID-19, [19] we hypothesized in our patient that the severe COVID-19-pneumonia induced a prothrombotic state, resulting in the descending aortic thrombosis. This thrombus likely embolized, leading to both renal and splenic infarction.

For arterial thromboprophylaxis, a few studies have demonstrated the importance of the use of antiplatelet therapy either alone or in combination with an anticoagulant in COVID-19-patients [20]. However, some authors propose to use routinely antiplatelet therapy with either low-dose aspirin (75-150 mg/d), or P2Y12 inhibitors such as clopidogrel and ticagrelor, especially in those who are deemed with a high risk of acute arterial thrombosis [21]. In contrast, a recent large study reported no effect of these antiplatelet therapies [22].

**Conclusion**

This case emphasizes the hypercoagulability state in COVID-19 patients leading to arterial thromboembolism. However, further studies are needed to confirm this novel and unusual form of thrombotic events associated with COVID-19. In the light of this case and current data, we suggest that physicians should adopt a high index of suspicion for associated thromboembolic events of to diagnose and manage this disease’s novel manifestations.
Authors' contribution

F. Laouan Brem: conception, literature review, analysis, data collection, writing - review & editing. T. Abu Al Tayef: conception, software, writing - review & editing. H. Rasras: conception, software, writing - review & editing. O. EL MAHI: conception, methodology, supervision. N. El Ouafi: conception, methodology, supervision. Z. Bazid: conception, methodology, supervision.

Source of financial support

There's no financial support.

Patient consent

Written informed consent was obtained from the patient for anonymized data to be published in this article.

References

[1] Roncon I, Zuin M, Barco S, et al. Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. Eur J Intern Med 2020;82:29–37 Dec Epub 2020 Sep 17. doi:10.1016/j.ejim.2020.09.006.

[2] Piazza G, Morrow DA. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA 2020;324(24):2548–9 Dec 22. doi:10.1001/jama.2020.23422.

[3] Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020;220:1–13 Jun Epub 2020 Apr 15. doi:10.1016/j.trsl.2020.04.007.

[4] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383(2):120–8 Jul Epub 2020 May 21. doi:10.1056/NEJMoai2015432.

[5] Ortel TL, Erkan D, Kitchens CS. How I treat catastrophic thrombotic syndromes. Blood 2015;126(11):1285–93 Sep 10 Epub 2015 Jul 15. doi:10.1182/blood-2014-09-551978.

[6] Singhania N, Bansal S, Nimmatoori DP, Eaz AA, McCullough PA, Singhania G. Current Overview on Hypercoagulability in COVID-19. Am J Cardiovasc Drugs 2020;20(5):393–403 Oct. doi:10.1007/s40256-020-00431-z.

[7] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395(10234):1417–18. doi:10.1016/S0140-6736(20)30937-5.

[8] Rey JR, Caro-Codón J, Poveda Pineda D, Merino JL, ÁM Iniesta, López-Sendón JL, et al. Arterial thrombotic complications in hospitalized patients with COVID-19. Rev Esp Cardiol (Engl Ed) 2020;73(9):769–71 Sep Epub 2020 May 23. doi:10.1016/j.rec.2020.05.008.

[9] Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging 2020;101(5):321–2 May Epub 2020 Apr 16. doi:10.1016/j.dii.2020.04.003.

[10] Woehl B, Lawson B, Jambert L, Tousch J, Chassani A, Hamade A. 4 cases of aortic thrombosis in patients with COVID-19. JACC Case Rep 2020;2(9):1397–401 Jul 15 Epub 2020 Jun 8. doi:10.1016/j.jaccr.2020.06.003.

[11] Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46(6):1089–98 Jun Epub 2020 May 4. PMID:32367170 .

[12] Indes JE, Koleilat I, Hatch AN, Choinaki K, Jones DB, Aldailami H, et al. Early experience with arterial thromboembolic complications in patients with COVID-19. J Vasc Surg 2021;73(2) Feb 381-389.e1 Epub 2020 Aug 28. doi:10.1016/j.jvascsurg.2020.07.089.

[13] Kashi M, Jacquin A, Dakhil H, Zaimi R, Mahé E, Tella E, et al. Severe arterial thrombosis associated with Covid-19 infection. Thromb Res 2020;192:75–7 Aug Epub 2020 May 16. doi:10.1016/j.thromres.2020.05.025.

[14] Lifen C, Kristin C, Anjali R, Michael W, Massimo N, et al. Arterial thrombosis in an ambulatory COVID-19 patient in recovery. J Vasc Endovasc Ther 2020;5(5):29 No No.

[15] Hanif M, Ali MJ, Haider MA, Naz S, Ahmad Z. Acute upper limb ischemia due to arterial thrombosis in a mild COVID-19 patient: a case report. Cureus 2020;12(9):e10349. doi:10.7759/cureus.10349.

[16] Kenizou D, Perrin C, Harzallah I, Bresson D, Allimant P, Calcaianu M, et al. Multiple arterial thrombosis in a 78-year-old patient: catastrophic thrombotic syndrome in COVID-19. CJCO Open 2021;3(2):198–200 Feb Epub 2020 Oct 2. doi:10.1016/j.cjco.2020.09.020.

[17] Madani MH, Leung ANC, Becker HC, Chan FP, Fleischmann D. Aorto-iliac/right leg arterial thrombosis necessitating limb amputation, pulmonary arterial, intracardiac, and ilio-caval venous thrombosis in a 40-year-old with COVID-19. Clin Imaging 2021;75:1–4 Jul Epub 2021 Jan 14. doi:10.1016/j.clinimag.2020.12.036.

[18] Goldman IA, Ye K, Scheinfeld MH. Lower-extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death. Radiology 2020;297(2):E263–9 Nov Epub 2020 Jul 16. doi:10.1148/radiol.202022348.

[19] Ramanathan M, Chueng T, Fernandez E, Gonzales-Zamora J. Concomitant renal and splenic infarction as a complication of COVID-19: a case report and literature review. Infez Med 2020;28(4):611–15 Dec 1.

[20] Vieccia M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res 2020;158:104950 Aug Epub 2020 May 23. doi:10.1016/j.phrs.2020.104950.

[21] Kow CS, Hasan SS. The use of antplatelet agents for arterial thromboprophylaxis in COVID-19. Rev Esp Cardiol (Engl Ed) 2021;74(1):114–15 Jan Epub 2020 Aug 28. doi:10.1016/j.rec.2020.08.009.

[22] Bradbury CA, Lawler PB, et al., REMAP-CAP Writing Committee for the REMAP-CAP Investigators Effect of antplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247–59. doi:10.1001/jama.2022.2910.